(Q43579359)

English

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia

scientific article published on 8 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 November 2017

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia (English)

1 reference

Europe PubMed Central

24 November 2017

1 reference

based on heuristic

inferred from title

author name string

S Wakita

1

1 reference

Europe PubMed Central

24 November 2017

H Yamaguchi

2

1 reference

Europe PubMed Central

24 November 2017

I Omori

3

1 reference

Europe PubMed Central

24 November 2017

K Terada

4

1 reference

Europe PubMed Central

24 November 2017

T Ueda

5

1 reference

Europe PubMed Central

24 November 2017

E Manabe

6

1 reference

Europe PubMed Central

24 November 2017

S Kurosawa

7

1 reference

Europe PubMed Central

24 November 2017

S Iida

8

1 reference

Europe PubMed Central

24 November 2017

T Ibaraki

9

1 reference

Europe PubMed Central

24 November 2017

Y Sato

10

1 reference

Europe PubMed Central

24 November 2017

T Todoroki

11

1 reference

Europe PubMed Central

24 November 2017

T Hirakawa

12

1 reference

Europe PubMed Central

24 November 2017

T Ryotokuji

13

1 reference

Europe PubMed Central

24 November 2017

K Arai

14

1 reference

Europe PubMed Central

24 November 2017

T Kitano

15

1 reference

Europe PubMed Central

24 November 2017

Y Mitamura

16

1 reference

Europe PubMed Central

24 November 2017

F Kosaka

17

1 reference

Europe PubMed Central

24 November 2017

K Dan

18

1 reference

Europe PubMed Central

24 November 2017

K Inokuchi

19

1 reference

Europe PubMed Central

24 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 November 2012

1 reference

Europe PubMed Central

24 November 2017

1 reference

Europe PubMed Central

24 November 2017

27

1 reference

Europe PubMed Central

24 November 2017

1044-1052

1 reference

Europe PubMed Central

24 November 2017

5

1 reference

Europe PubMed Central

24 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2012.317

0 references

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Outcome of patients with acute myelogenous leukemia after second salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

DNMT3A Mutations in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Recurring mutations found by sequencing an acute myeloid leukemia genome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Genetic variegation of clonal architecture and propagating cells in leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Drug resistance in mutant FLT3-positive AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

FLT3 as a therapeutic target in AML: still challenging after all these years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Clinical significance of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

21 January 2018

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.317

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.317

1 reference

Europe PubMed Central

24 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43579359&oldid=2101618983"